Drug Trial News

RSS

High-dose vitamin D3 cannot be recommended as treatment for metastatic colon cancer

A double-blind randomized phase 3 clinical trial led by Dana-Farber Cancer Institute researchers and conducted across several hundred cancer centers in the U.S. tested the addition of high-dose vitamin D3 to standard treatment for patients with untreated metastatic colorectal cancer.

16 Sep 2024

Early data shows mRNA-4359 may benefit patients with advanced solid cancers

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.

16 Sep 2024

New cancer drug shows encouraging results in Phase I/II trial

The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar ADCs and initial efficacy in heavily pretreated patients with advanced or metastatic solid tumors, according to interim data shared today at the 2024 European Society for Medical Oncology (ESMO) Congress by researchers from The University of Texas MD Anderson Cancer Center.

14 Sep 2024

New drug shows strong activity against brain metastases in HER2-positive breast cancer

A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2-positive breast cancer.

13 Sep 2024

Semaglutide and tirzepatide significantly improve weight loss and glycemic control in type 1 diabetes

Semaglutide and tirzepatide treatment lead to significant weight loss and improve blood sugar control in individuals with type 1 diabetes (T1D) who are living with overweight or obesity, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September) has found.

13 Sep 2024

Trial finds no benefit of adding nivolumab to tivozanib for advanced kidney cancer

In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the addition of the immune checkpoint inhibitor (ICI) nivolumab to treatment with tivozanib for patients with advanced clear cell renal cell carcinoma, a form of kidney cancer.

13 Sep 2024

Research highlights cardiovascular benefits of semaglutide for overweight adults with impaired kidney function

The anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with overweight or obesity who don't have diabetes, whether or not they also have impaired kidney function, according to new research to be presented at this year's Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).

13 Sep 2024

Early Phase I data shows promise for mRNA cancer immunotherapy in advanced solid cancers

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.

12 Sep 2024

Duffy-null phenotype may lead to unfair exclusion from cancer drug trials

Many clinical trials of new cancer drugs may be inappropriately excluding some people with "Duffy-null phenotype," a trait found predominantly in people of African or Middle Eastern descent, researchers at Dana-Farber Cancer Institute and Queen Mary University of London report in a new study.

12 Sep 2024

Women experience greater weight loss with tirzepatide compared to men

All doses of tirzepatide, a medication approved in the EU to treat type 2 diabetes and obesity, consistently reduced body weight in women and men, but women experienced greater weight loss, according to new post hoc research to be presented at this year's Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).

11 Sep 2024

Telisotuzumab vedotin shows promising results in asian patients with c-Met overexpressing NSCLC

The c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an acceptable safety profile in patients of Asian race with c-Met protein-overexpressing, epidermal growth factor receptor (EGFR) wildtype (WT), locally advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC), according to research presented today at the International Association for the Study of Lung Cancer's 2024 World Conference on Lung Cancer.

11 Sep 2024

Zongertinib shows promising efficacy in HER2 mutation-positive NSCLC

The HER2-specific tyrosine kinase inhibitor zongertinib was well tolerated and demonstrated promising efficacy in patients with HER2 mutation-positive non-small cell lung cancer, meeting the primary endpoint of the Beamion LUNG-1 Phase Ib Cohort 1 study, according to research presented today at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer.

11 Sep 2024

Taletrectinib shows high response rates and safety in ROS1+ lung cancer patients

The ROS1 tyrosine kinase inhibitor (TKI) taletrectinib demonstrated high overall and intracranial responses, and a favorable safety profile with low incidence of neurologic adverse events in TKI-naive and TKI-pretreated patients with ROS1+ non-small cell lung cancer (NSCLC).

11 Sep 2024

Pre-surgery chemotherapy shows promise for preserving vital organs in nasal and sinus cancer

Results from a clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) show a striking improvement for patients who received chemotherapy before surgery to remove advanced squamous cell-type cancer of the nose or sinus.

11 Sep 2024

Obesity medication liraglutide safe and effective in children under 12, research finds

The obesity medication liraglutide is safe and effective in children aged 6 to <12 years, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September), and published simultaneously in the New England Journal of Medicine (NEJM), has found.

10 Sep 2024

Once-a-day oral weight loss drug shows promising results in reducing body weight

Individuals who received a once-a-day oral weight loss drug lost up to 13% of their body weight over three months, the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September) will hear.

10 Sep 2024

Ifinatamab deruxtecan shows promising results in advanced small cell lung cancer

The antibody–drug conjugate ifinatamab deruxtecan (I-DXd) showed clinically meaningful responses in pretreated patients with extensive-stage small cell lung cancer (ES-SCLC), according to an interim analysis of the Phase 2 IDeate-Lung01 study.

9 Sep 2024

Gene therapy shows dramatic vision improvement for rare inherited condition

The vision of people with a rare inherited condition that causes them to lose much of their sight early in childhood was 100 times better after they received gene therapy to address the genetic mutation causing it.

5 Sep 2024

Alirocumab reduces dangerous coronary plaque and stabilizes high-risk lesions

Intensive LDL-C lowering with alirocumab significantly reduces high-risk coronary plaque burden, transforming unstable plaques into more stable phenotypes. This lesion-level analysis underscores the enhanced efficacy compared to vessel-level approaches.

4 Sep 2024

$FINEARTS-HF trial shows finerenone benefits for heart failure with preserved ejection fraction$

FINEARTS-HF trial shows finerenone benefits for heart failure with preserved ejection fraction

Finerenone reduced heart failure (HF) events and cardiovascular death in patients with HF and mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

2 Sep 2024

Drug Trial News

High-dose vitamin D3 cannot be recommended as treatment for metastatic colon cancer

Early data shows mRNA-4359 may benefit patients with advanced solid cancers

New cancer drug shows encouraging results in Phase I/II trial

New drug shows strong activity against brain metastases in HER2-positive breast cancer

Semaglutide and tirzepatide significantly improve weight loss and glycemic control in type 1 diabetes

Trial finds no benefit of adding nivolumab to tivozanib for advanced kidney cancer

Research highlights cardiovascular benefits of semaglutide for overweight adults with impaired kidney function

Early Phase I data shows promise for mRNA cancer immunotherapy in advanced solid cancers

Duffy-null phenotype may lead to unfair exclusion from cancer drug trials

Women experience greater weight loss with tirzepatide compared to men

Telisotuzumab vedotin shows promising results in asian patients with c-Met overexpressing NSCLC

Zongertinib shows promising efficacy in HER2 mutation-positive NSCLC

Taletrectinib shows high response rates and safety in ROS1+ lung cancer patients

Pre-surgery chemotherapy shows promise for preserving vital organs in nasal and sinus cancer

Obesity medication liraglutide safe and effective in children under 12, research finds

Once-a-day oral weight loss drug shows promising results in reducing body weight

Ifinatamab deruxtecan shows promising results in advanced small cell lung cancer

Gene therapy shows dramatic vision improvement for rare inherited condition

Alirocumab reduces dangerous coronary plaque and stabilizes high-risk lesions

FINEARTS-HF trial shows finerenone benefits for heart failure with preserved ejection fraction

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News